Novelix Pharmaceuticals Limited (BOM:536565)

Revenue by Segment

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Pharma Business	1.32B	295.09M	1.45M	2.13M	78.55M
Pharma Business Growth	348.47%	20232.03%	-31.92%	-97.29%	74.26%
Finance	-	159.58K	2.04M	2.73M	2.98M
Finance Growth	-	-92.19%	-25.06%	-8.43%	-10.78%
Investment in Shares	-	-	664.78K	2.43M	2.54M
Investment in Shares Growth	-	-	-72.64%	-4.29%	2544.79%
Trading in Shares	-	12.09M	41.15M	11.91M	7.56M
Trading in Shares Growth	-	-70.62%	245.41%	57.55%	-23.49%
Total	1.32B	307.34M	45.31M	19.20M	91.63M
Total Growth	330.59%	578.29%	135.96%	-79.04%	-4.41%

Revenue by Geography

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
India	1.32B	307.33M	45.31M	19.20M	89.13M
India Growth	330.60%	578.26%	135.96%	-78.45%	-7.01%
Total	1.32B	307.33M	45.31M	19.20M	89.13M
Total Growth	330.60%	578.26%	135.96%	-78.45%	-7.01%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 19, 2026

Data Sources Report a data error